1. Hepatitis C virus RNA is 5′-capped with flavin adenine dinucleotide
- Author
-
Sherwood, Anna V., Rivera-Rangel, Lizandro R., Ryberg, Line A., Larsen, Helena S., Anker, Klara M., Costa, Rui, Vågbø, Cathrine B., Jakljevič, Eva, Pham, Long V., Fernandez-Antunez, Carlota, Indrisiunaite, Gabriele, Podolska-Charlery, Agnieszka, Grothen, Julius E. R., Langvad, Nicklas W., Fossat, Nicolas, Offersgaard, Anna, Al-Chaer, Amal, Nielsen, Louise, Kuśnierczyk, Anna, Sølund, Christina, Weis, Nina, Gottwein, Judith M., Holmbeck, Kenn, Bottaro, Sandro, Ramirez, Santseharay, Bukh, Jens, Scheel, Troels K. H., and Vinther, Jeppe
- Abstract
RNA viruses have evolved elaborate strategies to protect their genomes, including 5′ capping. However, until now no RNA 5′ cap has been identified for hepatitis C virus1,2(HCV), which causes chronic infection, liver cirrhosis and cancer3. Here we demonstrate that the cellular metabolite flavin adenine dinucleotide (FAD) is used as a non-canonical initiating nucleotide by the viral RNA-dependent RNA polymerase, resulting in a 5′-FAD cap on the HCV RNA. The HCV FAD-capping frequency is around 75%, which is the highest observed for any RNA metabolite cap across all kingdoms of life4–8. FAD capping is conserved among HCV isolates for the replication-intermediate negative strand and partially for the positive strand. It is also observed in vivo on HCV RNA isolated from patient samples and from the liver and serum of a human liver chimeric mouse model. Furthermore, we show that 5′-FAD capping protects RNA from RIG-I mediated innate immune recognition but does not stabilize the HCV RNA. These results establish capping with cellular metabolites as a novel viral RNA-capping strategy, which could be used by other viruses and affect anti-viral treatment outcomes and persistence of infection.
- Published
- 2023
- Full Text
- View/download PDF